Patent details

EP2310415 Title: ANTIBODIES AGAINST FCRN AND USE THEREOF

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
EP2310415
WO Application Number:
US2009002536
Type:
European Patent Granted for NL
Status:
Patent in Force
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP09734929.4
WO Publication Number:
WO2009131702
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
United States of America (US)
Publications:

Dates

Filing date:
24/04/2009
Grant date:
11/10/2017
EP Publication Date:
20/04/2011
WO Publication Date:
29/10/2009
Claims Translations Received Date:
Claims Translation B1 Received Date:
29/12/2017
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
11/10/2017
EP B1 Publication Date:
11/10/2017
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
23/04/2029
Lapsed By Expiration Date:
Patent Validated Date:
13/01/2018
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
05/11/2021
 
 

 

Name:
Takeda Pharmaceutical Company Limited
Address:
1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, Japan (JP)

From:
05/11/2021
 
 

 

Name:
Bioverativ Therapeutics Inc.
Address:
225 2nd Avenue, 02451, Waltham, MA, United States of America (US)

Historical Applicant/holder

From:
05/11/2021
To:
05/11/2021

 

Name:
Dyax Corp.
Address:
300 Shire Way, 02421, Lexington, MA , United States of America (US)

From:
10/08/2018
To:
05/11/2021

 

Name:
Dyax Corp.
Address:
55 Network Drive, Burlington, MA 01803, United States of America (US)

From:
10/08/2018
To:
05/11/2021

 

Name:
Bioverativ Therapeutics Inc.
Address:
225 2nd Avenue, 02451, Waltham, MA, United States of America (US)

From:
11/10/2017
To:
10/08/2018

 

Name:
Dyax Corporation
Address:
300 Technology Square, CAMBRIDGE, MA 02139, United States of America (US)

From:
11/10/2017
To:
10/08/2018

 

Name:
Biogen Hemophilia Inc.
Address:
9 Fourth Avenue, Waltham, MA 02451, United States of America (US)

Agent

Name:
ir. W.J.J.M. Kempes
From:
12/01/2018
Address:
Dogio Patents Postbus 2350, 1200 CJ, Hilversum, Netherlands (NL)
To:

Inventor

1

Name:
TENHOOR, Christopher
Address:
Hopkinton MA 01748, United States of America (US)

2

Name:
MURUGANANDAM, Arumugam
Address:
Bangalore 560035, India (IN)

3

Name:
LADNER, Robert, Charles
Address:
Ijamsville MD 21754, United States of America (US)

4

Name:
WOOD, Clive
Address:
Boston, MA 02114, United States of America (US)

5

Name:
BITONTI, Alan, J.
Address:
Acton MA 01720, United States of America (US)

6

Name:
STATTEL, James
Address:
Hagerstown MD 21740, United States of America (US)

7

Name:
MCDONNELL, Kevin
Address:
Waltham MA 02451, United States of America (US)

8

Name:
LIU, Liming
Address:
Upper Dublin PA 19002, United States of America (US)

9

Name:
DUMONT, Jennifer
Address:
Groton MA 01450, United States of America (US)

10

Name:
SATO, Aaron
Address:
Richmond CA 94805, United States of America (US)

Priority

1

Priority Patent Number:
48500 P
Priority Date:
28/04/2008
Priority Country:
United States of America (US)

2

Priority Patent Number:
48152 P
Priority Date:
25/04/2008
Priority Country:
United States of America (US)

Classification

IPC or IDT classification:
C07K 16/28; G01N 33/68;

Publication

Bulletin

1

Bulletin Heading:
CO
Journal edition number:
49/21
Publication date:
08/12/2021
Description:
Changes in the Netherlands Patent Register

2

Bulletin Heading:
CO
Journal edition number:
42/18
Publication date:
10/10/2018
Description:
Changes in the Netherlands Patent Register

3

Bulletin Heading:
EP3
Journal edition number:
04/18
Publication date:
17/01/2018
Description:
European patents granted for the Netherlands in which a translation was filed ex Article 52 par. 1 of the NL Patent Law 1995

4

Bulletin Heading:
EP2
Journal edition number:
41/17
Publication date:
11/10/2017
Description:
European patents granted for the Netherlands

European Patent Bulletin

1

Issue number:
201750
Publication date:
13/12/2017
Description:
Document reprinted after correction (B8, B9)

2

Issue number:
201747
Publication date:
22/11/2017
Description:
Document reprinted after correction (B8, B9)

3

Issue number:
201746
Publication date:
15/11/2017
Description:
Application number/publication number of the divisional application (Art. 76) changed

4

Issue number:
201741
Publication date:
11/10/2017
Description:
Grant (B1)

Deed

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC202102374D
Date Registered:
05/11/2021
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
Baker & McKenzie Amsterdam N.V.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

1

Name:
Bioverativ Therapeutics Inc.
Address:
225 2nd Avenue, 02451, Waltham, MA, United States of America (US)

2

Name:
Takeda Pharmaceutical Company Limited
Address:
1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, Japan (JP)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Change of Address

Change Kind/ Decision Type:
Owner
Deed Number:
RC202102374A
Date Registered:
05/11/2021
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
Baker & McKenzie Amsterdam N.V.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Change of owner(s)

Change Kind/ Decision Type:
Change of owner(s) name
Deed Number:
RC201801443A
Date Registered:
10/08/2018
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
RWS Group (RW Translations Limited)
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

1

Name:
Dyax Corp.
Address:
55 Network Drive, Burlington, MA 01803, United States of America (US)

2

Name:
Bioverativ Therapeutics Inc.
Address:
225 2nd Avenue, 02451, Waltham, MA, United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
30/04/2026
Annual Fee Number:
18
Annual Fee Amount:
1200 Euro
Last Annual Payment Date:
19/03/2025
Last Annual Fee Paid Number:
17
Last Annual Fee Paid Amount:
1100 Euro
Payer:
Anaqua Services
Filing date Document type Document Description Number of pages File Type
09/10/2018 Outgoing Correspondence Letter registration deed 1 PDF /4/5/3/2/0/0800202354/docs/ep09734929.4_1_232141l118.pdf
10/08/2018 Request for Change First filed deed 4 PDF /4/5/3/2/0/0800202354/docs/ep09734929.4_2_rfc20180813031851492.pdf
12/01/2018 Outgoing Correspondence Letter no formal defects 1 PDF /4/5/3/2/0/0800202354/docs/ep09734929.4_3_186872l271.pdf
29/12/2017 Claims First filed claims 3 PDF /4/5/3/2/0/0800202354/docs/ep09734929.4_0_claims20171229153835060.pdf
29/12/2017 Incoming Correspondence Electronic Accompanying letter incoming document 2 PDF /4/5/3/2/0/0800202354/docs/ep09734929.4_4_incomingcorrespondenceelectronic20171229153835835.pdf